EUVIMEDDescoperă EUVIMED
Randomisierte kontrollierte StudieMultizentrische StudieOpen access

Efficacy and Safety of Mobile App–Based Metamemory Cognitive Training for Mild Cognitive Impairment: Multicenter Randomized Clinical Trial

Sunyoung Kang iD, Jung-In Lim iD, Lukas Stenzel iD, Keun You Kim iD, Eosu Kim iD, Hong Jun Jeon iD, Doo-Heum Park iD, Hyun Kook Lim iD, YongSoo Shim iD, Jae-Won Jang iD, Yeshin Kim iD, Sanghoon Lee iD and 1 more

JMIR mHealth and uHealth · 2026-01-19 · 14 · e73464

DOI: 10.2196/73464 ↗

At a glance

Randomisierte kontrollierte Studie in JMIR mHealth and uHealth, published online on 2026-01-19. Written by Sunyoung Kang and 12 co-authors. Institution: Department of Psychiatry & Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Major MEDLINE topics: Cognitive Dysfunction, Mobile Applications, Cognitive Behavioral Therapy. Cited 4 times so far (Crossref); 70 references. The full text is freely available in PubMed Central.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background

Metamemory training (MMT) offers a potential nonpharmacological approach to enhance cognitive function in individuals with mild cognitive impairment (MCI). While digital cognitive training improves accessibility, the effectiveness of mobile app–based MMT has not been evaluated in a randomized clinical trial.

Objective

We aimed to evaluate the efficacy and safety of a mobile app–based MMT program, ET-101 (Cogthera), compared to a sham device control group in individuals with MCI.

Methods

This multicenter, randomized controlled trial enrolled participants with MCI, recruited from 7 medical centers, and randomly assigned them to the ET-101 or control group (1:1 ratio). The intervention lasted 12 weeks, with a 12-week follow-up. The ET-101 group received metamemory-based multimemory strategy training and real-time feedback. Assessments of cognition, the daily activities of living, and the quality of life were conducted at baseline, week 12, and week 24. The primary outcome was the proportion of participants who showed cognitive improvement as assessed by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)-14 at weeks 12 and 24. Secondary outcomes included changes in the scores of scales assessing cognition, daily activities, and quality of life. Safety analysis assessed adverse events and their relation to digital therapeutics.

Results

In the full analysis set, 49 participants were included in the ET-101 group and 50 in the control group. At week 24, the proportion of responders who maintained or improved their ADAS-Cog-14 scores was significantly higher in the ET-101 group than in the control group (P=.002). Additionally, the ET-101 group showed a significant improvement in ADAS-Cog-14 scores at week 24 compared to baseline levels (estimates=–2.53; t265=–3.05; Bonferroni-adjusted P=.003). A subdomain analysis revealed significant improvements in the memory (estimates=–2.50; t264=–4.03; Bonferroni-adjusted P

Subjects

MeSH terms (MEDLINE)

Cognitive DysfunctionMobile ApplicationsCognitive Behavioral TherapyHumansMaleFemaleAgedMiddle AgedAged, 80 and overTreatment OutcomeNeuropsychological TestsQuality of LifeCognitive Training

Author keywords

cognitive declinecognitive trainingdigital therapeuticsmild cognitive impairmentmobile app–based cognitive training

Authors and institutions

  • Department of Psychiatry & Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Interdisciplinary Program in Cognitive Science, Seoul National University, Seoul, Republic of Korea.
  • Cogthera GmbH, Munich, Germany.
  • Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Metabolism-Dementia Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Psychiatry, Konkuk University Medical Center, Seoul, Republic of Korea.

ORCID profiles: Sunyoung Kang, Jung-In Lim, Lukas Stenzel, Keun You Kim, Eosu Kim, Hong Jun Jeon, Doo-Heum Park, Hyun Kook Lim, YongSoo Shim, Jae-Won Jang, Yeshin Kim, Sanghoon Lee, Kee Hyung Park

Cite

APA

Kang, S., Lim, J. I., Stenzel, L., Kim, K. Y., Kim, E., Jeon, H. J., Park, D. H., Lim, H. K., Shim, Y., Jang, J. W., Kim, Y., Lee, S., & Park, K. H. (2026). Efficacy and Safety of Mobile App–Based Metamemory Cognitive Training for Mild Cognitive Impairment: Multicenter Randomized Clinical Trial. JMIR mHealth and uHealth, 14, e73464. https://doi.org/10.2196/73464

Vancouver

Kang S, Lim JI, Stenzel L, Kim KY, Kim E, Jeon HJ, et al. Efficacy and Safety of Mobile App–Based Metamemory Cognitive Training for Mild Cognitive Impairment: Multicenter Randomized Clinical Trial. JMIR mHealth and uHealth. 2026;14:e73464. doi:10.2196/73464

BibTeX
@article{Kang2026,
  author = {Kang, Sunyoung and Lim, Jung-In and Stenzel, Lukas and Kim, Keun You and Kim, Eosu and Jeon, Hong Jun and Park, Doo-Heum and Lim, Hyun Kook and Shim, YongSoo and Jang, Jae-Won and Kim, Yeshin and Lee, Sanghoon and Park, Kee Hyung},
  title = {Efficacy and Safety of Mobile App–Based Metamemory Cognitive Training for Mild Cognitive Impairment: Multicenter Randomized Clinical Trial},
  journal = {JMIR mHealth and uHealth},
  year = {2026},
  volume = {14},
  pages = {e73464},
  doi = {10.2196/73464}
}
Start for free →